Raghunath Singh

Dr. Raghunath Singh

Centre for Addiction and Mental Health, Toronto, Ontario, Canada
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2016 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
LMLovish Marwaha
Lovish Marwaha
YBYashika Bansal
Yashika Bansal
Raghunath SinghRaghunath Singh
Raghunath Singh
PSPriyanka Saroj
Priyanka Saroj
RBRanjana Bhandari
Ranjana Bhandari
AKAnurag Kuhad
Anurag Kuhad

1 February 2019 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Raghunath SinghRaghunath Singh
Raghunath Singh
YBYashika Bansal
Yashika Bansal
BMBikash Medhi
Bikash Medhi
AKAnurag Kuhad
Anurag Kuhad

1 September 2018 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
YBYashika Bansal
Yashika Bansal
Raghunath SinghRaghunath Singh
Raghunath Singh
PSPriyanka Saroj
Priyanka Saroj
RSRupinder Kaur Sodhi
Rupinder Kaur Sodhi
AKAnurag Kuhad
Anurag Kuhad

21 May 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YBYashika Bansal
Yashika Bansal
Raghunath SinghRaghunath Singh
Raghunath Singh
IPIshwar Parhar
Ishwar Parhar
AKAnurag Kuhad
Anurag Kuhad
TSTOMOKO SOGA
TOMOKO SOGA
Depression is an incapacitating neuropsychiatric disorder. The serotonergic system in the brain plays an important role in the pathophysiology of depression. However, due to the often delayed and/or poor performance of selective serotonin reuptake inhibitors in treating depressive symptoms, the serotonergic system’s role in depression has recently been questioned further. Evidence from recent studies has suggested that increased inflammation and oxidative stress may play significant roles in the pathophysiology of depression. The consequences of these factors can lead to the neuroprogression of depression, which includes neurodegeneration, astrocyte apoptosis, reduced neurogenesis, reduced plasticity (neuronal and synaptic), and enhanced immunoreactivity. Specifically, increased proinflammatory cytokine levels have been shown to lead to the activation of the kynurenine pathway, which causes an increase in the production of quinolinic acid [QA, an N-Methyl-D-aspartate (NMDA) agonist] and decreases the synthesis of serotonin. QA exerts many deleterious effects in the brain via mechanisms including NMDA excitotoxity, increased oxidative stress, astrocyte degeneration, and neuronal apoptosis. QA may also act directly as a pro-oxidant. Additionally, the nuclear translocation of antioxidant defence factors, such as nuclear factor (erythroid-derived 2)-like 2 (Nrf2), is downregulated in depression. Hence, in the present review, we discuss the role of QA in increasing oxidative stress in depression by modulating the nuclear translocation of Nrf2 and thus affecting the synthesis of antioxidant enzymes.

1 May 2021 in NeuroToxicology
Verified
Journal Article
Closed access
RSRupinder Kaur Sodhi
Rupinder Kaur Sodhi
YBYashika Bansal
Yashika Bansal
Raghunath SinghRaghunath Singh
Raghunath Singh
PSPriyanka Saroj
Priyanka Saroj
RBRanjana Bhandari
Ranjana Bhandari
AKAnurag Kuhad
Anurag Kuhad

1 July 2017 in Pharmacology
Verified
Journal Article
Closed access
PDF file
NSNavdeep Singh
Navdeep Singh
YBYashika Bansal
Yashika Bansal
RBRanjana Bhandari
Ranjana Bhandari
LMLovish Marwaha
Lovish Marwaha
Raghunath SinghRaghunath Singh
Raghunath Singh
AKAnurag Kuhad
Anurag Kuhad
Intracerebral hemorrhage (ICH) contributes to 10-15% of all strokes and is a high risk factor for morbidity and mortality as compared to other subtypes of stroke, that is, cerebral ischemia and subarachnoid hemorrhage. Oxidative stress (OS)-induced neuroinflammation and neuronal cell death contribute towards the hallmarks of ICH. Spared antioxidant levels, increased inflammatory cytokines and free radicals in ICH lead to neuronal death and exaggerate the hallmarks of ICH. Intracerebroventricular (ICV) collagenase (COL-induced neuronal cell damage and cognitive deficits form a widely recognized experimental model for ICH. Naringin (NGN), a natural antioxidant bioflavonoid, has shown potent neuroprotective effects in different neurodegenerative diseases. However, its potential is least explored in pathological conditions, such as hemorrhagic stroke. This study is aimed at exploring the protective effects of NGN against ICV-COL induced behavioral, neurological and memory deficits in rats. ICV-ICH was induced by single, unilateral intrastriatal injection of COL (1 IU in 2 µL, ICV) over 10 min. From 2nd day onwards, NGN was administered in three different doses (10, 20, and 40 mg/kg; p.o.). Animals were subjected to a battery of behavioral tests to assess behavioral changes, including neurological scoring tests (cylinder test, spontaneous motility, righting reflex, horizontal bar test, forelimb flexion), actophotometer, rotarod, Randall Selitto and von Frey. Poststroke depression and memory deficits were estimated using forced swim test and Morris water maze test, respectively. Poststroke depression, neurological and cognitive deficits were mitigated dose dependently by NGN administration. NGN administration also attenuated the nitro-OS and restored tumor necrosis factor-α and endogenous antioxidant levels. Our research demonstrates that NGN has a protective effect against ICH-induced neurocognitive deficits, along with mitigation of oxido-nitrosative and inflammatory stress.